JP2022553908A5 - - Google Patents
Info
- Publication number
- JP2022553908A5 JP2022553908A5 JP2022521074A JP2022521074A JP2022553908A5 JP 2022553908 A5 JP2022553908 A5 JP 2022553908A5 JP 2022521074 A JP2022521074 A JP 2022521074A JP 2022521074 A JP2022521074 A JP 2022521074A JP 2022553908 A5 JP2022553908 A5 JP 2022553908A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence includes
- region amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025087525A JP2025134713A (ja) | 2019-10-11 | 2025-05-26 | Ｐｄ１およびｖｅｇｆｒ２二重結合剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1914747.9 | 2019-10-11 | ||
| GB201914747A GB201914747D0 (en) | 2019-10-11 | 2019-10-11 | PD1 and vegfr2 dual-binding agents |
| GBGB2013180.1A GB202013180D0 (en) | 2019-10-11 | 2020-08-24 | Pd1 and vegfr2 dual-binding agents |
| GB2013180.1 | 2020-08-24 | ||
| PCT/EP2020/078427 WO2021069670A1 (en) | 2019-10-11 | 2020-10-09 | Pd1 and vegfr2 dual-binding agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025087525A Division JP2025134713A (ja) | 2019-10-11 | 2025-05-26 | Ｐｄ１およびｖｅｇｆｒ２二重結合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553908A JP2022553908A (ja) | 2022-12-27 |
| JP2022553908A5 true JP2022553908A5 (enExample) | 2023-10-17 |
| JP7689116B2 JP7689116B2 (ja) | 2025-06-05 |
Family
ID=68619556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521074A Active JP7689116B2 (ja) | 2019-10-11 | 2020-10-09 | Ｐｄ１およびｖｅｇｆｒ２二重結合剤 |
| JP2025087525A Pending JP2025134713A (ja) | 2019-10-11 | 2025-05-26 | Ｐｄ１およびｖｅｇｆｒ２二重結合剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025087525A Pending JP2025134713A (ja) | 2019-10-11 | 2025-05-26 | Ｐｄ１およびｖｅｇｆｒ２二重結合剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20240101674A1 (enExample) |
| EP (3) | EP4041763B1 (enExample) |
| JP (2) | JP7689116B2 (enExample) |
| KR (1) | KR20220091490A (enExample) |
| CN (2) | CN121758618A (enExample) |
| AU (1) | AU2020365021B2 (enExample) |
| CA (2) | CA3156096C (enExample) |
| DK (1) | DK4041763T3 (enExample) |
| ES (1) | ES3027238T3 (enExample) |
| FI (1) | FI4041763T3 (enExample) |
| GB (2) | GB201914747D0 (enExample) |
| HR (1) | HRP20250523T1 (enExample) |
| HU (1) | HUE071341T2 (enExample) |
| IL (1) | IL292158A (enExample) |
| LT (1) | LT4041763T (enExample) |
| PL (1) | PL4041763T3 (enExample) |
| PT (1) | PT4041763T (enExample) |
| RS (1) | RS66837B1 (enExample) |
| SI (1) | SI4041763T1 (enExample) |
| WO (1) | WO2021069670A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| GB201914747D0 (en) | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
| CN116143935A (zh) * | 2021-11-22 | 2023-05-23 | 杭州翰思生物医药有限公司 | 重组抗体及其应用 |
| CN119654343A (zh) * | 2022-08-09 | 2025-03-18 | 上海济煜医药科技有限公司 | 一种靶向pd-1和vegf的抗体及其应用 |
| CN118620082A (zh) * | 2023-03-10 | 2024-09-10 | 南京维立志博生物科技有限公司 | 靶向vegf途径和pd-1的双特异性抗原结合蛋白、其组合物和用途 |
| WO2026150132A1 (en) | 2025-01-12 | 2026-07-16 | BioNTech SE | Combination therapy comprising an rna cancer vaccine and a multispecific binding agent targeting pd-1/pd-l1 and vegf/vegfr for cancer treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| ES2742379T3 (es) * | 2012-05-31 | 2020-02-14 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| MA43028B1 (fr) | 2015-10-02 | 2021-09-30 | Hoffmann La Roche | Anticorps bispécifiques pour pd1 et tim3 |
| CN109893654B (zh) * | 2017-12-11 | 2021-07-27 | 江苏恒瑞医药股份有限公司 | Vegfr抑制剂治疗肿瘤的方法 |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201803746D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| JP7883848B2 (ja) | 2018-11-06 | 2026-07-02 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 腫瘍を治療するための薬物の調製におけるファミチニブと組み合わせた抗ｐｄ－１抗体の使用 |
| GB201914747D0 (en) | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
-
2019
- 2019-10-11 GB GB201914747A patent/GB201914747D0/en not_active Ceased
-
2020
- 2020-08-24 GB GBGB2013180.1A patent/GB202013180D0/en not_active Ceased
- 2020-10-09 EP EP20789105.2A patent/EP4041763B1/en active Active
- 2020-10-09 SI SI202030611T patent/SI4041763T1/sl unknown
- 2020-10-09 JP JP2022521074A patent/JP7689116B2/ja active Active
- 2020-10-09 CA CA3156096A patent/CA3156096C/en active Active
- 2020-10-09 CA CA3289307A patent/CA3289307A1/en active Pending
- 2020-10-09 PL PL20789105.2T patent/PL4041763T3/pl unknown
- 2020-10-09 AU AU2020365021A patent/AU2020365021B2/en active Active
- 2020-10-09 EP EP25212556.2A patent/EP4671279A3/en active Pending
- 2020-10-09 FI FIEP20789105.2T patent/FI4041763T3/fi active
- 2020-10-09 KR KR1020227014433A patent/KR20220091490A/ko active Pending
- 2020-10-09 LT LTEPPCT/EP2020/078427T patent/LT4041763T/lt unknown
- 2020-10-09 US US17/768,013 patent/US20240101674A1/en not_active Abandoned
- 2020-10-09 ES ES20789105T patent/ES3027238T3/es active Active
- 2020-10-09 CN CN202511932691.3A patent/CN121758618A/zh active Pending
- 2020-10-09 HU HUE20789105A patent/HUE071341T2/hu unknown
- 2020-10-09 EP EP25159487.5A patent/EP4570824A3/en not_active Withdrawn
- 2020-10-09 HR HRP20250523TT patent/HRP20250523T1/hr unknown
- 2020-10-09 DK DK20789105.2T patent/DK4041763T3/da active
- 2020-10-09 CN CN202080075802.2A patent/CN114981301B/zh active Active
- 2020-10-09 PT PT207891052T patent/PT4041763T/pt unknown
- 2020-10-09 WO PCT/EP2020/078427 patent/WO2021069670A1/en not_active Ceased
- 2020-10-09 RS RS20250448A patent/RS66837B1/sr unknown
-
2022
- 2022-04-11 IL IL292158A patent/IL292158A/en unknown
-
2025
- 2025-02-18 US US19/056,312 patent/US12479920B2/en active Active
- 2025-05-26 JP JP2025087525A patent/JP2025134713A/ja active Pending
- 2025-10-22 US US19/366,430 patent/US20260167726A1/en active Pending